Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
This study has been completed.
First Received: May 7, 2002   Last Updated: June 27, 2008   History of Changes
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00036101
  Purpose

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.


Condition Intervention Phase
Bipolar Disorder
Drug: aripiprazole
Phase III

Study Type: Interventional
Study Design: Treatment

Resource links provided by NLM:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036101

  Show 27 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Study ID Numbers: CN138-074
Study First Received: May 7, 2002
Last Updated: June 27, 2008
ClinicalTrials.gov Identifier: NCT00036101     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Bipolar I Disorder

Additional relevant MeSH terms:
Disease
Tranquilizing Agents
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents
Pharmacologic Actions
Affective Disorders, Psychotic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Mood Disorders
Aripiprazole
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009